Cell Medica, a UK-based biotech firm, received an $8.7 million grant from the Cancer Prevention & Research Institute of Texas that will allow the firm to develop an off-the-shelf chimeric antigen receptor T-cell therapy that engineers a donor's immune cells to detect cancer antigens in patients with hematologic cancers and solid tumors.
UK biotech gains $8.7M in funding for CAR-T therapy development
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.